Hemogenyx in development of ApbHC, a novel type of humanized mouse

Vladislav Sandler, Chief Executive Officer of Hemogenyx Pharmaceuticals, said the potential of the ApbHC, a new generation of our humanized mice, has allowed the company to rapidly obtain in vivo data on the efficacy of the company’s CDX antibodies against AML.

He said that the company is actively developing and expanding the potential use of the ApbHC for disease modeling, the development of new therapeutics, and biodefense applications. “Our ApbHC has also generated significant interest from third parties who also see its potential for disease modeling and drug development,” he said.

The company said in a press release that as with AHC, it believes that the ApbHC will be of considerable interest to other drug developers and initial interest shown is promising.